• hello@whatnews.in
  • Home
  • Business
  • World
  • Contact US
Home»business»Pfizer CEO pockets $33M for 2022 after 36% pay hike (NYSE:PFE)
business

Pfizer CEO pockets $33M for 2022 after 36% pay hike (NYSE:PFE)

whatnewsBy whatnewsMarch 19, 2023No Comments2 Mins Read
Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
Share
Facebook Twitter LinkedIn Pinterest Email


Win McNamee

Pfizer (NYSE:PFE) Chief Executive and Chairman Albert Bourla will likely become one of the top-earning pharma CEOs for 2022 after the pharma giant took his total compensation to $33.0M handing him a ~36% pay hike for last year.

Meanwhile, Johnson & Johnson (JNJ), whose former helmsman Alex Gorsky was the highest-paid pharma CEO in 2021, rewarded its new CEO Joaquin Duato, with a $13.1M package, indicating a ~51% decline in the company’s top executive pay.

Gorsky relinquished his CEO role in 2022 after a decade-long tenure as its chairman and CEO, while Bourla, 61, is now serving in his fourth year in the dual leadership position.

In 2021, Bourla earned $24.4M, after a ~16% rise from the prior year as the company’s top line jumped ~95% YoY thanks to its blockbuster COVID-19 shot which accounted for over 45% of the top line.

However, Pfizer’s (PFE) explosive growth sputtered, and its share price fell as the pandemic subsided. The company revenue reached $10.3B in 2022, which implies a ~23% YoY rise, but still indicates more than double that in 2020.

After a ~59% climb in 2021, its share price tumbled ~13%, underperforming its mega-cap pharma rivals, as indicated in this graph.

Bourla’s 2022 pay also demonstrates a ~42% rise in his equity-based compensation and a ~4% decline in his non-equity-based incentives, which stand at $18.8M and $7.7M, respectively, according to Pfizer’s latest proxy statement.

Meanwhile, Stéphane Bancel, CEO of rival COVID vaccine maker Moderna (MRNA), earned $19.4M in 2022 after the Massachusetts-based biotech raised his total compensation by ~7%.

Having recorded $18.5B in revenue for 2021, Moderna’s (MRNA) top line reached $19.3B last year, indicating a ~4% YoY rise while its share price plummeted ~29%, following a ~141% jump in the prior year.

Pfizer (PFE) says that the company’s executive compensation implies a median of compensation data from its big pharma peers and a group of non-pharmaceutical companies of similar size and complexity.

The pharma peers it has considered include AbbVie (ABBV) and Eli Lilly (LLY), where top management earned $26.3M and $21.4M for 2022, indicating a ~10% rise and ~1% decline in their pay from the prior year, respectively.



Source link

Post Views: 6
33M CEO hike NYSEPFE Pay pfizer pockets
Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
Previous ArticleNike attracts bull/bear debate ahead of earnings (NYSE:NKE)
Next Article UBS reportedly reaches deal to buy Credit Suisse for more than $2 billion
whatnews
  • Website

Related Posts

BofA Securities maintains Netflix at Buy

March 24, 2023

TELUS prices $500M of 4.95% Sustainability-Linked bonds

March 24, 2023

Jefferies says Regeneron’s Dupixent drug could drive shares 15% higher

March 24, 2023
Add A Comment

Leave A Reply Cancel Reply

Subscribe to Updates

Get the latest sports news from SportsSite about soccer, football and tennis.

Advertisement
About Us
Privacy Policy
Contact Us
© Copyright 2023. All rights reserved.